CommercialCoverageMedium impact
06.02.32d, Multigene Expression Assays for Predicting Recurrence in Colon Cancer (Independence Administrators)
Independence Blue Cross·Oncology, Gastroenterology, General Surgery·Medical Policy
Effective date
Apr 29, 2026
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued their medical policy 06.02.32d regarding multigene expression assays for predicting recurrence in colon cancer. This is a policy reissue with an effective date of April 29, 2026, indicating updated coverage guidelines for genetic testing in colon cancer patients.
Action Required
Before April 29, 2026: Review updated policy 06.02.32d for multigene expression assays in colon cancer recurrence prediction. Clinical and billing teams should verify current coverage criteria and prior authorization requirements for genetic testing services. Update any internal protocols to align with Independence Administrators' revised guidelines.